InvestorsHub Logo
Post# of 252504
Next 10
Followers 832
Posts 119984
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 193937

Thursday, 07/30/2015 8:48:32 PM

Thursday, July 30, 2015 8:48:32 PM

Post# of 252504
BNTC's lead program—TT-034 gene therapy for HCV—won't fly, IMO. Having foreign DNA permanently residing in host nuclei seems like an unwarranted safety risk when you can cure the disease with 12 weeks of oral therapy.

BNTC says TT-034 has the benefit of preventing re-infection, but that’s an over-engineered solution to a minor problem.

p.s. On the roadshow webcast, the CEO asserted that BNTC’s US IPO is justified by ALNY’s lofty valuation, LOL.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.